UOC
ASTX

UBS O'Connor’s ASTEX PHARMACEUTICALS, INC COM ASTX Stock Holding History

UBS O'Connor’s Portfolio ASTX Stock Details ASTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q3 		– Sell
-188,000
Closed -$773K – 652
2013
Q2 		$773K Buy
+188,000
New +$1.01M 0.01% 391

Other funds holding ASTX

BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
TAL
TIG Advisors LLC New York $2.16B AUM 72.99% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
CM
Corvex Management New York $2.52B AUM 25.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
WIC
Water Island Capital New York $896M AUM 107.59% 1-Year Est. Return
SAM
Sandell Asset Management New York $179M AUM 65.55% 1-Year Est. Return

UBS O'Connor's ASTX Position: Q3 2013 in Review

UBS O'Connor sold out of ASTEX PHARMACEUTICALS, INC COM (ASTX) in Q3 2013, closing a stake of 188,000 shares — an estimated $773K sold.

UBS O'Connor first reported a position in ASTX in Q2 2013 and held it in 1 quarter. The position peaked at $773K in Q2 2013. 123 funds tracked by Wall St. Rank hold ASTX as of Q3 2013.

  • UBS O'Connor reported no remaining ASTEX PHARMACEUTICALS, INC COM position as of Q3 2013 after selling out during the quarter.
  • UBS O'Connor sold 188,000 ASTEX PHARMACEUTICALS, INC COM shares in Q3 2013, an estimated $773K.
  • UBS O'Connor first reported a position in ASTEX PHARMACEUTICALS, INC COM in Q2 2013 and held it in 1 quarter.
  • UBS O'Connor's ASTEX PHARMACEUTICALS, INC COM position peaked at $773K in Q2 2013.
  • 123 funds tracked by Wall St. Rank held ASTEX PHARMACEUTICALS, INC COM as of Q3 2013.

Based on UBS O'Connor's 13F filing for Q3 2013, filed 14 Nov 2013.